#ESC26: Trial failure clouds future of AstraZeneca’s heart disease gene silencer

MUNICH — The surprise failure of a high-profile study of AstraZeneca’s and Ionis Pharmaceuticals’ Wainua can be attributed to patients in the trial also taking a Pfizer drug for the same condition, the head of the ...